EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinguishing true recurrence from second primary breast cancer using molecular clonality analysis in clinical practice

Tess I M Snellen, Esther H Lips, Linda J W Bosch, Terry Wiersma, Astrid N Scholten, Michaël Noë, Marie-Jeanne T F D Vrancken Peeters, Vincent O Dezentjé

Cancer Treatment and Research Communications · 2026 · 49 · 101436

DOI: 10.1016/j.ctarc.2026.101436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Tess I M Snellen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. Electr…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: A second breast cancer (BC) in the ipsilateral breast or regional lymph nodes may represent a true recurrence (TR) or second primary (SP) tumor. When clinicopathological evaluation is inconclusive, molecular clonality analysis (MCA) can establish a clonal relationship between tumor pairs. This study describes the findings and success rates of MCA techniques used to distinguish second ipsilateral BC as TR or SP in a real-world cohort. METHODS: This retrospective cohort study included patients who underwent MCA for a second ipsilateral locoregional BC at the Netherlands Cancer Institute (NKI) between 2000 and 2024. The primary objective was to describe the findings and success rates of MCA techniques. The secondary objective was to compare MCA-based with clinicopathological classifications according to the Jobsen Morphology method. RESULTS: Ninety-nine MCAs were performed in 85 patients. Targeted next-generation sequencing (NGS) panel analysis was most frequently applied (53.5%), followed by loss of heterozygosity (LOH) (31.3%), and copy number variation (CNV) analysis (15.2%). Success rates were highest for CNV analysis (93.3%), followed by targeted NGS panel (73.6%) and LOH analysis (61.3%). A substantial discordance (36.9%) was observed between the MCA-based classification and the Jobsen Morphology method. Clinicopathological assessment demonstrated limited predictive value for MCA-based TRs (PPV 72.5%, NPV 28.6%). CONCLUSION: MCA provides a conclusive classification of second ipsilateral BCs as TR or SP in most cases. Substantial discordance between MCA-based and Jobsen Morphology classification in this selected population was observed. Integration of MCA into the diagnostic workflow may provide additional diagnostic information when clinicopathological classification is uncertain.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerIpsilateral locoregional recurrenceMolecular clonality analysisSecond primaryTrue recurrence

Autor:innen und Institutionen

  • Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. Electronic address: t.snellen@nki.nl.
  • Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. Electronic address: e.lips@nki.nl.
  • Pathology and Molecular Diagnostics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, Netherlands. Electronic address: l.bosch@nki.nl.
  • Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. Electronic address: t.wiersma@nki.nl.
  • Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. Electronic address: a.scholten@nki.nl.
  • Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. Electronic address: m.p.m.noe@amsterdamumc.nl.

Zitieren

APA

Snellen, T. I. M., Lips, E. H., Bosch, L. J. W., Wiersma, T., Scholten, A. N., Noë, M., Vrancken Peeters, M. T. F. D., & Dezentjé, V. O. (2026). Distinguishing true recurrence from second primary breast cancer using molecular clonality analysis in clinical practice. Cancer Treatment and Research Communications, 49, 101436. https://doi.org/10.1016/j.ctarc.2026.101436

Vancouver

Snellen TIM, Lips EH, Bosch LJW, Wiersma T, Scholten AN, Noë M, et al. Distinguishing true recurrence from second primary breast cancer using molecular clonality analysis in clinical practice. Cancer Treatment and Research Communications. 2026;49:101436. doi:10.1016/j.ctarc.2026.101436

BibTeX
@article{Snellen2026,
  author = {Snellen, Tess I M and Lips, Esther H and Bosch, Linda J W and Wiersma, Terry and Scholten, Astrid N and Noë, Michaël and Vrancken Peeters, Marie-Jeanne T F D and Dezentjé, Vincent O},
  title = {Distinguishing true recurrence from second primary breast cancer using molecular clonality analysis in clinical practice},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101436},
  doi = {10.1016/j.ctarc.2026.101436}
}
Kostenlos starten →